Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deoxymab-1
- Development stage
- Unknown
- Lead developer
- Patrys
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Deoxymab-1 (also known as PAT-DX1) is a first-in-class, cell-penetrating antibody fragment developed by Patrys Ltd. It is a re-engineered and optimized version of the 3E10 lupus autoantibody. Deoxymab-1 utilizes the equilibrative nucleoside transporter 2 (ENT2) to cross the blood-brain barrier and enter cell nuclei, where it binds to DNA and inhibits DNA damage repair (DDR) pathways. This mechanism makes it synthetically lethal to cancer cells with existing homologous recombination (HR) defects, such as those with BRCA1/2 mutations or PTEN deficiency. It is currently being evaluated in clinical trials for the treatment of glioblastoma and other advanced solid tumors.
- Other names
- PAT-DX1 nanoparticle conjugatePAT-DX-1 nanoparticle conjugatePAT-DX 1 nanoparticle conjugate
02
Targets
ENT2 (Equilibrative nucleoside transporter 2)DNA
Beyond the preview
Go deeper on Deoxymab-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deoxymab-1.